FinlandFinland

Buying back a heart treatment

05.06.2009

Espoo – Finnish pharmaceutical and dia­gnostics company OrionA/S has agreed to pay Abbott US$18m to re-acquire the rights to the intravenous formulation of its heart failure treatment levosimendan, which is marketed as Simdax.
Following the deal, Orion will hold the rights to Simdax in all regions outside of Latin America, where Abbott will retain the marketing rights for the product. Abbott is also to receive a 30% annual royalty from Orion between 2009-2013, as well as a US$15m milestone payment if the cumulative net sales of the product reach US$12.5m after the transaction has closed.
Orion never relinquished the rights to Simdax in Scandinavia and Iceland, but once the deal closes, it will begin marketing the drug in the rest of Europe as well. Simdax’s global sales were around US$40m last year.

FinlandFinland

11.02.2011

Helsinki – Using laser light to destroy tumour cells lodged in lymphatic vessels can halt the spread of cancer, Finnish researchers headed by Tuomas Tammela have demonstrated. Their approach to destroy the tumour cells, which use...

FinlandFinland

03.11.2010

Turku/Freiburg – EU researchers led by scientists at the University of Turku have begun designing a bacterium able to produce liquefied petroleum gas (LPG) from sunlight. “We have all the parts to put the ability for production...

FinlandFinland

19.09.2010

Rajamäki/Darmstadt – A cooperation project between AB Enzymes Oy and Royal Oy has resulted in the discovery of an enzyme that enables washing temperature to be dropped to as low as 10° C. The project is being funded by the SymBio...

FinlandFinland

08.07.2010

Turku – Finland’s Faron Pharmaceuticals Ltd. has announced a cooperation with German biotech company Priaxon AG to create new scaffold structures to modify the AOC3-protein function and its ligand interaction with orally...

FinlandFinland

09.06.2010

Tampere – Short people are at greater risk of developing heart disease than tall people, according to a meta-analysis of 52 populations-based studies including 3 million people by Finnish researchers (Eur. Heart J.,...

FinlandFinland

12.05.2010

Reykjavik – Researchers from the Icelandic bio­tech company deCODE – together with colleagues from 23 institutions in a dozen countries – have determined that genetic factors influence both nico­tine dependence and the incidence...

FinlandFinland

11.05.2010

Turku – Finnish Biotie Therapies Corp. confirmed that its oral phospho­diesterase 4 inhibitor ELB353 has proven safe and pharmacologically active in a Phase I study. Pharmacokinetic data point to the suitability of ELB353 for a...

FinlandFinland

07.03.2010

Helsinki/Hinxton – Finland has pledged EUR1.85m to help create world-class bio­informatics, biobanking and translational research infrastructures, the European Bioinformatics Institute (EBI) at the European Molecular Laboratory...

FinlandFinland

04.02.2010

Helsinki –Finland is investing EUR1.9m in creating world class bioinformatics, biobanking and translational research infrastructures. The investment comes as part of the linkage of three large EU projects ELIXIR, BBMRI, and...

Displaying results 11 to 20 out of 96

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-finland/browse/1/article/buying-back-a-heart-treatment.html

Events

All Events

Stock list

All quotes

TOP

  • ADDEX3.13 CHF4.68%
  • CO.DON3.15 EUR4.30%
  • BB BIOTECH146.25 EUR2.17%

FLOP

  • WILEX2.35 EUR-5.24%
  • SANTHERA89.15 CHF-3.10%
  • EVOTEC2.93 EUR-2.33%

TOP

  • SANTHERA89.15 CHF31.2%
  • CO.DON3.15 EUR26.0%
  • PAION3.01 EUR24.4%

FLOP

  • ADDEX3.13 CHF-22.3%
  • EVOTEC2.93 EUR-21.2%
  • MEDIGENE3.95 EUR-15.1%

TOP

  • SANTHERA89.15 CHF2117.7%
  • CO.DON3.15 EUR250.0%
  • PAION3.01 EUR189.4%

FLOP

  • CYTOS0.24 CHF-94.0%
  • MERCK KGAA67.67 EUR-40.6%
  • THERAMETRICS0.09 CHF-40.0%

No liability assumed, Date: 17.09.2014


Current issue

All issues

Product of the week

Products